Skyla (Levonorgestrel) Patent Expiration, LOE Window & CMS Spending

Skyla (Levonorgestrel) by Bayer: FDA Orange Book LOE 2029-09-16, 0 AB generics, $5.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN203159 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2029-09-16
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.3M
2024 Medicare Part D Spend$12K
2024 Medicaid Spend$5.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.